Barclays Boosts McKesson (MCK) Price Target, Says Shares Likely to Stay in Favor

Group 1 - McKesson Corporation (NYSE:MCK) is recognized as one of the top dividend stock picks by Goldman Sachs [1] - Barclays has raised its price target for McKesson to $1,050 from $960, maintaining an Overweight rating, indicating that the stock is expected to remain favorable among investors seeking safety in healthcare [2] - McKesson completed the sale of its retail and distribution businesses in Norway to NorgesGruppen, marking a significant step in its restructuring efforts to exit European operations [3] Group 2 - The divestiture allows McKesson to focus on growth areas, particularly in Oncology, Multispecialty, and Biopharma Services, which are now central to its long-term strategy [4] - McKesson operates as a diversified healthcare services company, aiming to improve health outcomes and support patient care across its network [4]